Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| CSI-Glucagon (Double-Blind) | Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr. Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide | 0 | None | 0 | 3 | 0 | 3 | View |
| Placebo | Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump. Placebo: Isotonic saline | 0 | None | 0 | 2 | 0 | 2 | View |
| CSI-Glucagon (Open-Label) | Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr. Glucagon: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide | 0 | None | 0 | 5 | 0 | 5 | View |